SL
RCUS icon

Salomon & Ludwin’s Arcus Biosciences RCUS Stock Holding History

Salomon & Ludwin’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8K Sell
996
-59
-6% -$1.46K ﹤0.01% 880
2026
Q1 		$24.2K Buy
1,055
+257
+32% +$5.55K ﹤0.01% 951
2025
Q4 		$17.4K Hold
798
– – ﹤0.01% 1014
2025
Q3 		$10.7K Buy
+798
New +$8.3K ﹤0.01% 1258

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Salomon & Ludwin's RCUS Position: Q2 2026 in Review

Salomon & Ludwin reduced its Arcus Biosciences (RCUS) stake by 5.6% in Q2 2026, selling an estimated $1.46K and leaving 996 shares worth $28.8K. The position accounts for ﹤0.01% of the portfolio, ranked #880.

Salomon & Ludwin first reported a position in RCUS in Q3 2025 and has held it in 4 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Salomon & Ludwin held 996 shares of Arcus Biosciences worth $28.8K as of Q2 2026.
  • Salomon & Ludwin sold 59 Arcus Biosciences shares in Q2 2026, an estimated $1.46K.
  • Arcus Biosciences made up ﹤0.01% of Salomon & Ludwin's portfolio in Q2 2026, its #880 holding.
  • Salomon & Ludwin first reported a position in Arcus Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Salomon & Ludwin's 13F filing for Q2 2026, filed 7 Aug 2026.